吡咯他尼(Piretanide)是一种新的袢利尿药,适于充血性心力衰竭的治疗。作者采用双盲、随机、平行、安慰剂对照的多中心试验,评价了吡咯他尼的疗效、安全性和耐受情况。 28名男性和10名女性充血性心衰病人口服给予吡咯他尼,起始剂量为6mg,如不能达到预定的治疗目标可逐日递增至最高日剂量24mg(分2次服用)。在28天试验期内测定尿量和钠、钾含量,并定期作体检和实验 Piretanide is a new diuretic that is suitable for the treatment of congestive heart failure. The authors evaluated the efficacy, safety, and tolerability of piretanide in a double-blind, randomized, parallel, placebo-controlled, multicentre trial. 28 male and 10 female patients with congestive heart failure were given piretanide orally at a starting dose of 6 mg. Day 2 could be increased daily up to a maximum daily dose of 24 mg (given in 2 doses) if the intended target of treatment was not achieved. Urine and sodium and potassium levels were determined during the 28-day trial period, and regular physical exams and experiments were performed